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Sllmmary 
Inhibitors of nitric oxide synthase (NOS) have been reported to increase mean arterial pressure 
in animal models of sepsis and recently have been given to patients in septic shock. However, 
controlled studies to determine the effects of these agents on cardiovascular function and survival 
in awake animal models of sepsis have not been reported. To examine the therapeutic potential 
of NOS inhibition in septic shock, we challenged canines with endotoxin (2 or 4 mg/kg i.v.) 
and treated them with either normal saline or N~~  (10 or 1 mg/kg/h), the most 
specific inhibitor available for the isoform of NOS implicated in septic shock. Endotoxemic animals 
treated  with  N~-amino-t-arginine  (n  =  11)  had  higher  systemic  and  pulmonary  vascular 
resistance indices (SVKI and PVKI, p  ~< 0.033) and decreased heart rates (p  =  0.009), cardiac 
indices (CI, p  =  0.01), oxygen delivery indices (p  =  0.027), and oxygen consumption indices 
(p  -  0.046) compared with controls (n  =  6). Moreover, N'~  increased mor- 
tality rates after endotoxin challenge (10 of 11 vs. 1 of 6 controls, p  =  0.005). Administration 
of t-arginine  did not improve survival or alter the cardiopulmonary effects of N~~  - 
arginine, which suggests that inhibition of NOS  may not have been competitive,  In normal 
animals, N~176  alone (n  =  3) increased SVtLI (p  =  0.0008)  and mean arterial 
pressure (p =  0.016), and decreased CI (p =  0.01) compared with saline-treated controls (n =  3), 
but, at the high dose, also produced neuromuscular rigidity and seizure-like activity that was 
not apparent in the endotoxemic model. Thus, the mortality rate from endotoxemia increased 
either because of NOS inhibition per se or because of properties unique to N~'-amino-L-arginine, 
or both. 
D 
espite antibiotic therapy and advances in critical care, 
septic shock is associated with a high mortality rate 
(1, 2). Approximately 50% of patients who die of septic shock 
have persistent hypotension and low systemic vascular resis- 
tance refractory to vasopressor therapy (3-5). New evidence 
suggests that overproduction of endothelium-derived relaxing 
factor (EDRF) 1, recently identified as nitric oxide (NO) (6) 
Portions of this material were presented at the May 1991 National Meeting 
of the American Federation for Clinical Research, Seattle, WA (Clin. Res. 
39:321a [abstr.]). 
1 Abbreviations used in this paper: CBC, complete blood count; CI, cardiac 
index; DO2I, oxygen delivery index; EDRF, endothelium-derived  relaxing 
or a closely related nitrosothiol (7, 8), contributes to the de- 
velopment of sepsis-induced hypotension (9).  A  calcium- 
independent isoform of nitric oxide synthase (NOS) can be 
induced in cultured endothelial cells by interferon-'y com- 
bined with bacterial LPS (endotoxin), TNF, or IL-1 (10-12), 
and in vascular smooth muscle cells in vitro after stimulation 
factor;  EK, extraction ratio; HR, heart rate; L-AKG, L-arginine; LVEE 
left ventricular ejection fraction, MAP, mean arterial pressure; NAA, N '~ 
amino-t-arginine;  NOS, nitric oxide synthase; PCWP, pulmonary capillary 
wedge pressure; PVKI, pulmonary vascular resistance index; SVI, stroke 
volume index;  SVR.I, systemic vascular resistance index;  VO2I,  oxygen 
consumption index. 
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form of NOS is responsible for the excess production of NO 
in sepsis, which leads to the development of shock (9, 14, 15). 
Some t-arginine  analogs reversibly inhibit  NOS,  restore 
endotoxin-induced loss of catecholamine vasomotor respon- 
siveness in vivo (16,  17), and reverse hypotension in animal 
models of septic shock.  N'~  (18,  19) has 
been shown in anesthetized animals to reverse endotoxin and 
TNF-induced hypotension (9,  20-22).  Most recently,  N ~- 
methyl-t-arginine  and another  NOS inhibitor,  N~-nitro-t - 
arginine methyl ester, were reported to increase systemic vas- 
cular resistance and blood pressure in three patients with septic 
shock (23, 24). Together, these studies support the hypoth- 
esis  that  production  of excess NO is a contributor  to the 
hypotension of septic shock,  and suggest  a potential  ther- 
apeutic role for inhibitors of NOS as antihypotensive agents 
in  this condition. 
However, inhibition of endogenous NO production may 
be harmful.  Administration of N~-methyl-L-arginine  to anes- 
thetized rats and canines has been shown to increase renal 
vascular resistance (25) and decrease renal blood flow (26, 
27). The use of this NOS inhibitor in awake canines results 
in dose-related increases  in basal epicardial coronary artery 
tone (28). Further,  N'~-methyl-L-arginine increases  capillary 
leak and enhances intestinal damage in rats and depresses cardiac 
output in anesthetized canines given endotoxin (21, 29). High 
doses  of N~-methyl-t-arginine  (300  mg/kg)  administered 
after endotoxin challenge can precipitate cardiovascular col- 
lapse and death in anesthetized  rats (22). 
Most previous investigations have examined the cardiovas- 
cular effects of short-term infusions of N~-methyl-t-arginine 
in the presence of general anesthetics, which may also pro- 
duce significant hemodynamic changes (30).  Further, studies 
using NOS inhibitors in large animal models of sepsis and 
in humans  have not been designed to determine the effect 
of these agents on survival.  In this study, we evaluated the 
therapeutic value of a continuously infused NOS inhibitor 
by serially following cardiopulmonary function, laboratory 
parameters,  and survival in awake canines challenged  with 
intravenous  endotoxin.  N~-amino-t-arginine  was  used  in 
these experiments  because it is a potent  NOS inhibitor  in 
vivo (31, 32), is the most specific inhibitor available for the 
induced isoform of NOS (15),  has not been reported to be 
significantly metabolized to the substrate t-arginine (unlike 
N~-methyl-t-arginine  (33), and is readily water soluble (un- 
like N'~-nitro-t-arginine). 
Materiah and Methods 
Reagents.  N~-amino-t-arginine was prepared as the lyophilized 
hydrochloride salt by Dr. Owen W. Grif~th at Cornell University 
Medical College 0 2, 34). The drug was reconstituted with ~/rogen- 
free normal saline and passed through a 22-/~m filter (Millex-GV; 
Millipore, Bedford, MA) before intravenous administration. Es&e- 
richia coli 0111:B4 endotoxin and L-arginine (Sigma Chemical Co., 
St. Louis, MO) were suspended in pyrogen-free normal saline for 
intravenous injection. Ceftriaxone (Rocephin|  Hoffman LaRoche 
Inc., Nutley, NJ) was reconstituted with pyrogen-free sterile water. 
Experimental Groups (Table 1) and Study Design (Fig. 1):  23 2-yr- 
old, purpose-bred, 8-13 kg beagles were studied. A baseline compre- 
hensive hemodynamic evaluation was performed for each animal 
at least 3 d before endotoxin challenge, as described previously (35, 
36). Briefly, arterial and thermodilution,  balloon-tipped,  pulmo- 
nary artery catheters were inserted in awake animals to obtain serial 
hemodynamic measurements (monitor model 90603; Spacelabs Inc., 
Redmond, WA) before and after an intravenous volume infusion 
(40 ml/kg Ringer's  solution  over 30 rain).  Left ventricular ejec- 
tion fractions (LVEF) were determined by radionuclide ventriculog- 
raphy (35). 
At time 0 h (Fig. 1), 17 animals received a 1- or 2-h intravenous 
infusion of endotoxin,  2 mg/kg/h, delivered using a micropump 
(Infu-Med  TM 300; Medfusion, Inc., Duluth, Georgia). 11 of these 
17 animals were given a 22-h, continuous,  N~-amino-t-arginine 
intravenous infusion at either 1 or 10 mg/kg/h after a loading dose 
(see Table 1). t-arginine was administered to 4 of the 11 N~-amino  - 
r-arginine-treated animals at 1, 10, 20 or 50 mg/kg/h after a loading 
dose (Table 1) to evaluate its ability to competitively reverse NOS 
inhibition  (9,  19, 20). The remaining  six endotoxin-challenged 
animals served as controls and received only normal saline at a rate 
equivalent  in  ml/h  to  that  of  N~-amino-t-arginine  infusion 
(0.9-1.2 ml/h). Six normal animals not challenged with endotoxin 
received N~-amino-t-arginine  alone at 1 mg/kg/h (n  =  1), or 10 
mg/kg/h (n  =  2), or an equal volume of normal saline (n  =  3). 
Ceftriaxone,  100 mg/kg, was injected intravenously immediately 
before and 22 h after endotoxin challenge to prevent catheter-related 
infection. All animals received 10 ml/kg/h Ringer's  solution in- 
travenously continuously for 6 h after endoto~dn challenge. 40 ml/kg 
of Ringer's solution was infused intravenously in all animals over 
30 rain immediately before time 0, I0, 14, and 22 h. Hemodyaamic 
measurements and blood for laboratory analysis were obtained at 
0, 2, 6,  10,  14,  18, and 22 h.  Simultaneous radionuclide LVEFs 
were determined  at 6 and 22 h.  All catheters  were removed at 
24 h and the animals were returned  to individual cages for 3-10 d 
of close observation depending  upon their  clinical status. 
Laboratory Analysis.  Blood samples for quantitative bacterial cul- 
ture were collected into 1.5-ml isolator tubes (DuPont Medical Prod- 
ucts Department, Wilmington, DE) at 0 and 22 h after endotoxin 
challenge just before the dose of ceftriaxone. Serial dilutions of the 
lysed samples were plated for bacterial colony quantitation.  Serum 
and whole blood were analyzed by an outside source (MetPath Mid- 
Atlantic  Regional Laboratory, Rockville, MD) for serum chem- 
istry and complete blood count (CBC) using standard automated 
methods. Arterial and mixed venous blood gases were determined 
using an automated system (288 Blood Gas System and 2500 Co- 
oximeter; Ciba-Coming Diagnostic  Corp., Medifield, MA). The 
N~-amino-r-arginine  solution was assayed for endotoxin contam- 
ination by Dr. H. Donald Hochstein (Division of Product Quality 
Control, Food and Drug Administration,  Bethesda, MD) using 
a limulus amebocyte lysate gel test (Associates  of Cape Cod, Woods 
Hole, MA). Plasma endotoxin concentrations were determined as 
previously described using a kinetic, chromogenic  limulus lysate 
assay (MA Bioproducts,  Walkersville, MD) (37). 
Animal Care.  The protocol  used in this study was approved 
by the Clinical Center Animal Care and Use Committee of the 
National  Institutes  of Health.  Every effort was made by a team 
of experienced veterinarians, physicians, and research technicians 
to keep the animals comfortable within the constraints of the pro- 
tocol. Animals were euthanized  if they appeared to be suffering 
in the judgment of the veterinarians or the investigators. 
Cardiopulmonary Cakulations and Statistics.  The methods used 
for the measurement and calculation of hemodynamic and LVEF 
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consumption (VOz) were calculated from measured values using 
standard formulae. Extraction ratio (ER) was calculated as VO2/ 
DOz.  The following  parameters were either measured directly 
from stripchart recordings or calculated using standard formulae: 
mean arterial pressure (MAP, mm Hg), systemic and pulmonary 
vascular resistance indices (SVRI and PV1LI, respectively, dyn.sec/ 
cmS.kg), cardiac index (CI,  ml/min.kg), heart rate (HK, beats/ 
min), LVEF, pulmonary capillary  wedge pressure (PCWP, mm Hg), 
stroke volume index (SVI, ml/kg), VO2 index (VO2I, ml/min-kg), 
and DO2 index (DO2I, ml/min.kg). 
Serial effects of endotoxin alone and serial effects of N~-amino  - 
L-arginine in  endotoxin-challenged  animals were  analyzed  by 
analysis of  variance (ANOVA) (39). A three-way ANOVA was con- 
structed with treatment group, dog nested within group,  time, 
and group-time interaction effects  extracted. A Tukey  multiple com- 
parisons procedure (39) or a Dunnett test (40) for comparing  to 
a common baseline was used to adjust iv values. Survival data were 
analyzed using Fisher's exact test. 
Results 
Survival and Clinical Manifestations.  Continuous intrave- 
nous N~~  administration decreased survival 
after intravenous endotoxin challenge (Table 1 and Fig. 2). 
The survival rates of  canines that received either 2 or 4 mg/kg 
of endotoxin plus normal saline did not differ significantly. 
This was also true for the endotoxin-challenged animals treated 
with either 1 or 10 mg/kg/h of N'~  10-d 
survival rates of the combined control groups (n  =  6) and 
the treatment groups (n  =  7) were 83 and 14%, respectively 
(Fig. 2, p  =  0.029). Two dogs in the low dose N~-amino  - 
t-arginine group were euthanized at 24 and 144 h and con- 
sidered nonsurvivors in keeping with the experimental pro- 
tocol (see Materials and Methods). One was preterminal and 
the other had bilateral hind limb paralysis  as a result of the 
experiment. The addition of a continuous t-arginine infu- 
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Figure 1.  Experimental  design. (Bars) Duration of infusions of endo- 
toxin, N'+-amino-r-arginine,  t-arginine, and Ringer's solution  as indicated. 
(Open arrows) Times when a 30-min intravenous infusion of 40 ml/kg 
Ringer's solution  was administered. (Solid  arrows)  Times  when physiologic 
measurements were  performed.  Baseline  (B) measurements  were  obtained 
at least 3 d before endotoxin challenge (0 h). 
Table  1.  Experimental  Croups 
Dose 
Number 
of dogs  Endotoxin  NAAt  10 d Survival (%) 
Endotoxin 
challenged 
NS" 
NAA 
NAA + 
L-arginineS 
Normal 
NS 
NAA 
.  mg/kg  mg/gg/h 
2  2  2  (100) 
4  4  3  (75) 
2  2  10  0  (0) 
5  4  1  I (20) 
4  4  1  0 (0) 
3  3 (100) 
2  10  0  (0) 
1  1  1 (100) 
* NS normal saline. 
t N,0-amino-t-arginine  (NAA) at 1 mg/kg/h or 10 mg/kg/h preceded 
by a 10 or 20 mg/kg NAA loading dose, respectively. 
s t-arginine at 1, 10, 20, or 50 mg/kg/h preceded  by a 1, 10, 200, or 
200 mg/kg IV loading dose, respectively. 
sion at 1,  10, 20, or 50 mg/kg/h did not improve survival 
(Fig.  2).  Two  animals  (nonsurvivors) in  this  group  were 
euthanized in preterminal states.  The animal that received 
L-arginine at 10 mg/kg/h was euthanized at 24 h, and the an- 
imal that received ~-arginine at 50 mg/kg was euthanized 
at 36 h. Combining data from all animals that received endo- 
toxin plus N~  with or without t-arginine 
(n  --  11), revealed a 10-d survival rate of 9.1% (p  =  0.005 
vs. saline-treated controls). During the study, no clinical differ- 
ences were noted between these groups. 
Because N~~  increased mortality after en- 
dotoxin challenge in this modal, normal animals were studied 
during an infusion of either N'~  or normal 
saline. The infusion of N~-amino-t-arginine at 10 mg/kg/h 
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Figure 2.  Survival  vs. time  in endotoxin-chaUenged  canines  treated  with 
either normal saline (controls, o---o),  N~-amino-t-arginine (NAA, 
~--O),  or NW-amino-t-arginine plus t-arginine (NAA  + L-ARC, 
k--~). 
1177  Cobb et al. in two animals was stopped at 6 and 14 h because of the onset 
of muscular hypertonicity,  myoclonus, and seizure-like ac- 
tivity. Because of persistent hypertonicity, the animals were 
euthanized 9 and 10 h, respectively, after discontinuation of 
N'~-amino-r-arginine.  The animal that received N'~  - 
t-arginine at 1 mg/kg/h and those that received only normal 
saline  experienced no untoward  sequelae. 
Hemodynamic and Blood Gas Analysis.  Differences (2 values) 
between groups are presented in this and the following sec- 
tion based upon ANOVA. Means (_+ SE) and time points at 
which these differences were significant are shown in Figs. 
3,  4,  and 5. 
Data from the normal animals that received N=-amino-t - 
arginine alone (n =  3) were pooled and compared with values 
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Figure 3.  Serial  changes (mean  -+  SE) in (A) SVRI; (B) MAP; (C) 
CI; and (D) SVI in normal dogs given a 22-h infusion of normal saline 
(o--o) or N"-amino-t-arginine (H).  *p <  0.05,  comparing N '~ 
amino-t-arginine to normal saline treatment at same time point. 
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Figure 4.  Serial  changes (mean  _+  SE) in (A) SVRI; (B) MAP; (C) 
PCWP; (D) PVRI; (E) CI; (F) HR; (G) SVI; and (H) LVEF in dogs chal- 
lenged with endotoxin (time 0 h) and treated with a 22-h infusion of normal 
saline (O---o) or N'~-amino-t-arginine (e--e).  *p < 0.05, comparing 
the value at the indicated time point to t  =  0 h in normal saline-treated 
canines to examine the effect of endotoxin,  tp <  0.05, comparing N '~ 
amino-t-arginine to normal saline treatment at the same time point. 
from animals that received only normal saline (n  =  3). N ~~ 
amino-t-arginine  increased SVRI (2  =  0.0008)  and MAP 
(2  =  0.016) and decreased CI (2  =  0.01) and SVI (0.014) 
compared with  normal  saline  (Fig.  3).  Decreases in DO2I 
and  VO2I  in  N'~-amino-t-arginine-treated  animals  ap- 
proached, but did not reach, statistical significance  (2 =  0.07 
and 0.08,  respectively, data not shown).  N'~-amino-t-argi - 
nine did not have significant effects on HK, PCWP, or LVEF 
(2 1> 0.30 for each parameter compared with normal saline, 
data not  shown).  Blood gas analysis  revealed  a decrease in 
arterial bicarbonate concentrations  (16.5  -+  1.5 vs. 21.0  _+ 
0.6 mM/L, p  =  0.004)  and  an  increase  in  arterial  lactate 
(1.90  +  0.09 vs. 0.33  +  0.07 mM/liter, p  =  0.002)in normal 
animals  treated  with  N'~  compared with 
normal saline at 22 h. N'~  animals 
also had a lower mixed venous oxygen (P,O2) at 2 h com- 
pared with  those that  received normal  saline  (32  +  1 vs. 
45  _+  3 mm  Hg, p  =  0.002). 
Because there were no significant differences in any hemo- 
dynamic variable between groups of animals  that  received 
either the tow (n  =  2) or high dose (n  =  4) of endotoxin, 
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Figure 5.  Serial  changes in (A) 
DO2I; (B) VO2I; and (C) ElL in 
dogs  challenged with  endotoxin 
(time 0 h) and treated with a 22-h 
infusion of normal saline (O---O) 
or NO-amino-t-arginine (O--O). 
*p < 0.05 comparing the value at 
the indicated time point to t  =  0 
h in normal saline-treated canines 
to examine the effect of endotoxin. 
tp < 0.05, comparing N'~-amino  - 
t-arginine  to normal  saline treat- 
ment at same time point. 
values from these animals were pooled for analysis (n  =  6). 
Compared to values at 0 h, endotoxin infusion decreased MAP, 
CI,  SVI,  and LVEF  and increased  SVRI,  PVRI,  HR,  and 
PCWP (p <  0.05 for each parameter, Fig. 4). Endotoxin chal- 
lenge  also led  to  significant  decreases  in  arterial  pH  (p  = 
0.0001),  bicarbonate concentrations  (p  --  0.0001),  and base 
excess (p  =  0.0001), compared to values at 0 h (Table 2). Addi- 
tionaUy, there was a significant increase in ER (2  =  0.01), but 
no statistically significant effect on DO2I or VO2I (Fig.  5). 
There were no  statistically  significant  differences  in  any 
of the cardiopulmonary parameters measured in endotoxin- 
challenged dogs that were treated with N~-amino+arginine 
at  either  the low  or high  dose,  with  (n  =  4)  or without 
(n  =  7) t-arginine. Thus, in the absence of significant differ- 
ences,  data  from  all  animals  treated  with  N~'-amino+ 
arginine were pooled to maximize the ability to detect any 
Nr  effect.  Combined  data  (n  =  11) 
demonstrated that treatment of endotoxin challenged animals 
with  N'~-amino-l.-arginine  increased  SVP, I  (p  =  0.008), 
PVRI  (p  =  0.047),  and  arterial lactate levels (p  =  0.046) 
and decreased HIL (p  =  0.009),  CI (p  =  0.01),  arterial pH 
(p  =  0.04), DO2I (p  =  0.027),  and VO2I (p  =  0.046) com- 
pared with  saline-treated controls  (Figs.  4  and 5,  Table 2). 
Differences between N~  and saline-treated 
groups for other cardiopulmonary values were not significant. 
Laboratory Analysis.  Endotoxin  infusion  resulted  in  a 
significant rise in plasma endotoxin levels from undetectable 
at 0 h to 1330  +  405 endotoxin units (EU)/ml and 3682  _+ 
1462 EU/ml at 2 h  in the saline and N~-amino-r-arginine - 
treated groups, respectively. Differences between these groups 
were not  significant.  Treatment  with  N~-amino-I.-arginine 
either with or without r-arginine had no effect on any labo- 
ratory values in endotoxemic animals (data not  shown, p  > 
0.05).  Blood culture data were available at 0  and  22  h  for 
all but two of the animals studied  (one received endotoxin 
alone and the  other  endotoxin  plus  N'~ 
none of the 21 animals tested was bacteremic. The endotoxin 
concentrations of the N'~-amino-t-arginine preparations were 
all g0.036 EU/ml (g3.6 pg/ml reference endotoxin). Animals 
thus received <10 pg/kg/d of reference endotoxin equivalent 
by way of the  N~  infusion. 
Discussion 
N~-amino-t-arginine unexpectedly increased mortality in 
this  canine model of endotoxic  shock.  The drug increased 
SVRI but decreased HR,  CI, DO2I,  and VO2I during  en- 
Table  2.  Arterial Blood Gas Analysis in Endotoxin-challenged Canines 
Normal saline  N~-amino-L-arginineLI 
Time  0  h  10  h  22  h  0  h  10  h  22 
pH,  7.41  _+  0.02*  7.31  +  0.01'  7.22  +  0.01'  7.36  _+  0.01  7.29  +_  0.03  7.09  _+  0.04S 
P,CO2  (mmHg)  32  +  2  28  _+  2  29  _+  2  34  _+  1  21  +  2S  37  +_  5 
P,O2  (mmHg)  115  _+  6  105  _+  5  97  _+  7  103  _+  3  99  _+  7  80  +_  8 
PrO2  (mmHg)  57  _+  10  44  _+  2  44  +  0  45  _+  3  38  -+  2  42  +_  4 
,HCO3(mM/L)  19.7  _+  0.7  13.4  _+  1.0'  12.0  +  0.8*  19.1  _+  0.4  9.8  _+  0.9  11.0  _+  0.7 
=BE (mM/L)  -3.4  _+  0.5  -10.4  +  1.0'  -14.2  _+  0.8*  -4.8  _+  0.4  -14.0  _+ 0.8  -18.2  +_  1.4 
=lactate (mM/L)  0.47  _+  0.06  0.74  +_  0.12  0.48  _+  0.06  0.49  +  0.08  1.3  _+  0.2 s  0.52  _+  0.17 
* Values shown  as mean  +  SE. 
t p <  0.05 compared within  the same group to values at time 0 h. 
s p <  0.05 compared with normal saline-treated group  at the same time point. 
II Pooled data from endotoxin-challenged animals that received N'~-amino-t-arginine with and without L-arginine. 
1179  Cobb et al. dotoxemia. Administration of L-arginine, a substrate reported 
to competitively reverse the effects of NOS inhibitors,  in- 
cluding N~'-arnino-t-arginine (9, 31, 34), failed to improve 
survival or to alter the hemodynamic profile of endotoxic 
shock in animals treated concomitantly with N'~-amino-t  - 
arginine.  In normal (nonendotoxemic) dogs,  N~-amino-t  - 
arginine increased SVRI and MAP and decreased CI and SVI. 
Further, this compound caused a previously unreported tox- 
icity manifested as muscular hypertonicity, myoclonus, and 
seizure-like activity that was apparent  in the two normal 
animals given 10 mg/kg/h N~-amino-t-arginine. 
The increase in SVRI and decrease in CI associated  with 
N~-methyl-t-arginine infusion are consistent with previous 
findings on the use of NOS inhibitors at similar doses in 
anesthetized animals given endotoxin (9, 21). Notably, N '~- 
amino-L-arginine, a related NOS inhibitor, has been reported 
to decrease CI by depressing SVI in both normal and endo- 
toxin-chaUenged  animals  under  pentobarbital  anesthesia 
(21).  However, we observed a difference in the N'~  - 
t-arginine-associated decrease in CI between our normal and 
endotoxemic dogs. Normal dogs treated with N~'-amino-t  - 
arginine developed a depressed CI because of a decrease in 
SVI without significant change in HR. In contrast, endotox- 
emic dogs  treated with  N'~  developed a 
depressed CI due to a decrease in HR without significant 
change in SVI.  There was no evidence that  N'~-amino-L - 
arginine had a direct effect on myocardial performance (as 
measured by LVEF) in normal dogs, and it did not alter the 
fall in LVEF characteristic of endotoxic shock (41).  These 
results are not consistent with a direct role for NO in the 
pathogenesis of myocardial depression during sepsis (42). Fur- 
ther, the lack of an effect on LVEF would argue against N ~- 
amino-r-arginine-induced global myocardial ischemia. 
Most previous laboratory studies have used NOS inhibi- 
tors to treat endotoxin or cytokine-induced shock in anesthe- 
tized canines (9, 20, 21). In our study, general anesthesia was 
not used because these agents have marked effects on cardio- 
vascular function and autonomic reflexes that could mask or 
augment the effect of either endotoxin or NOS inhibition. 
Anesthesia itself can produce hypotension, splanic vasocon- 
striction,  dose-dependent cardiac depression, and blunting 
of normal autonomic reflexes (30). Pentobarbital, the anesthetic 
used in some previous studies of NOS inhibition (9, 21), is 
a myocardial depressant that causes an increase in HR and 
a decrease in SVI (30, 43). In addition, positive pressure ven- 
tilation is often used in conjunction with anesthetics and may 
further alter cardiopulmonary function, thus making data in- 
terpretation difficult. Notably, in our study in awake canines, 
N~-amino-L-arginine had only modest effects on endotoxin- 
induced hypotension compared with the results obtained in 
anesthetized models (9).  The role, if any, of nitric oxide in 
anesthetic-induced hypotension has not been investigated. 
t-arginine was  not  found to improve survival or affect 
cardiopulmonary parameters in endotoxemic dogs given N ~- 
amino-t-arginine. It has been demonstrated in vitro that in- 
hibition of NOS by r-arginine analogs may not be reversible 
under certain conditions (44, 45). Most previous studies using 
t-arginine in vivo to reverse the effects of NOS inhibitors, 
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in particular N~-methyl-r-arginine, measured hemodynamic 
changes immediately after rapid intravenous infusions of NOS 
inhibitors and t-arginine (9,  19, 20, 36).  It seems likely in 
the present investigation that  inhibition  of NOS by N ~'- 
amino-t-arginine was not reversed by the continuous adminis- 
tration of t-arginine, based on the lack of a cardiovascular 
effect. The continuous infusion of N~'-amino-r-arginine in 
our study may have resulted in irreversible,  rather than com- 
petitive, inhibition of NOS. This hypothesis is supported by 
a recent report on the use of these agents to treat human 
septic shock (23),  as the duration of action of 1 mg/kg N '~ 
methyl-t-arginine appeared to increase after successive intra- 
venous bolus infusions. 
The adverse  impact of N~-amino-t-arginine on survival 
after endotoxin challenge was unexpected and the exact mech- 
anism for this enhanced mortality remains unknown. The 
continuous infusion of N'~  may have raised 
serum or tissue concentrations of this agent to levels sufficient 
to cause toxicity. The relatively short-lived hemodynamic 
effects of NOS inhibitors in animal models (9,  20, 23, 31) 
have led to the recommendation (22) and use (23, 27) of these 
agents as continuous infusions. However, as mentioned above, 
the pharmacologic profile and metabolic fate of these agents 
have not been thoroughly characterized. Further, endotoxemia 
may alter the metabolism of NOS inhibitors.  N~-amino-L  - 
arginine alone demonstrated a previously unreported neu- 
romuscular toxicity in  normal animals,  manifested by an 
increase in neuromuscular excitability.  It is possible that N ~- 
amino-L-arginine or one of its metabolites is epileptogenic 
or might have disrupted normal guanidine metabolism, as 
abnormal serum levels of other guanidine compounds have 
been linked to seizure activity (46,  47).  We cannot deter- 
mine from this study whether the neuromuscular toxicity 
of N~  contributed to the increased mor- 
tality of endotoxin challenge.  N~'-amino-t-arginine at I rag/ 
kg/h did not cause obvious toxicity in the one normal an- 
imal tested, but did increase the mortality of endotoxemia. 
It  is notable that  N~-amino-t-arginine did have poten- 
tially harmful effects during endotoxemia, as demonstrated 
by N~-amino-r-arginine-induced decreases in CI, DO2I, and 
VOzI.  It is possible  that DO2I may have become inadequate 
to meet metabolic demands, leading to the observed fall in 
VO2I  and an increase in mortality (48).  This relationship, 
however, cannot be confirmed from the present investigation, 
though it is supported by the higher arterial lactate levels 
and lower pH measured in the endotoxemic animals treated 
with  N'~  Other  investigators  have  re- 
ported that NOS inhibitors worsen endotoxin-induced cap- 
illary leak and gastrointestinal damage in rodents, which sug- 
gests that NO may be important in maintaining vascular in- 
tegrity and organ blood flow in sepsis (29).  However, we 
did not observe enhanced endotoxin-induced hepatic damage 
(reflected by serial measures of liver function tests)  in our 
N~'-amino-t-arginine-treated canines, as has been reported 
in mice given N'~-methyl-r-arginine (49).  This may repre- 
sent species-related differences, NOS inhibitor differences, or 
both. 
It is important to consider the potentially harmful hemo- 
Mortality Rates after Endotoxin Challenge dynamic effects of N~-amino-t-arginine in the context of the 
limitations of this particular model of septic  shock.  The 
hemodynamic profile of human septic shock, characterized 
by a high CI and a low SVRI, was not simulated by the en- 
dotoxin model used in this study, despite the large volumes 
of intravenous fluids (200  ml/kg/d) used for resuscitation. 
It is not clear that an NOS inhibitor-induced increase in SVRI 
would be harmful in septic  shock patients with a high CI 
and low SVRI. The ability of NOS inhibitors to reverse the 
catecholamine hyporesponsiveness of the septic vasculature 
(16, 17, 50) may be useful clinically for the treatment of refrac- 
tory septic shock, especially in patients who cannot tolerate 
high doses of vasopressors. However, based upon the results 
of this investigation, we conclude that prolonged adminis- 
tration of N~'-amino-I.-arginine  is harmful to normal and 
endotoxin-challenged canines, and that it should not be used 
in patients. Clearly, the neurotoxic potential of some NOS 
inhibitors must be appreciated and more fully studied, ideally 
in unanesthetized animals. In addition, the pharmacokinetic 
and pharmacodynamic profiles of NOS inhibitors need to be 
determined in vivo before the optimal route and timing of 
administration can be established. 
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